- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/28 - Antiandrogens
Patent holdings for IPC class A61P 5/28
Total number of patents in this class: 172
10-year publication summary
|
4
|
5
|
3
|
11
|
7
|
14
|
11
|
9
|
8
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Aragon Pharmaceuticals, Inc. | 76 |
9 |
| The University of British Columbia | 1547 |
8 |
| Suzhou Kintor Pharmaceuticals, Inc. | 64 |
6 |
| Taisho Pharmaceutical Co., Ltd. | 849 |
6 |
| University of Tennessee Research Foundation | 765 |
5 |
| Provincial Health Services Authority | 198 |
4 |
| Bayer Schering Pharma AG | 309 |
3 |
| Bayer Pharma AG | 1009 |
3 |
| The Johns Hopkins University | 5913 |
3 |
| Astellas Pharma Inc. | 1039 |
3 |
| British Columbia Cancer Agency Branch | 178 |
3 |
| Fundacio Institut de Recerca Biomedica (irb Barcelona) | 78 |
3 |
| Institucio Catalana de Recerca I Estudis Avancats | 398 |
3 |
| Jiangsu Hengrui Medicine Co., Ltd. | 686 |
3 |
| Sloan-Kettering Institute for Cancer Research | 630 |
3 |
| Oncternal Therapeutics, Inc. | 35 |
3 |
| Pfizer Inc. | 3409 |
2 |
| Koninklijke Philips N.V. | 25938 |
2 |
| Sumitomo Chemical Company, Limited | 8968 |
2 |
| Astellas US LLC | 168 |
2 |
| Other owners | 96 |